Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Hypersensitivity Reactions: Immune-Complex Reactions

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum...

Hypersensitivity Reactions: Cytolytic Reactions

Hypersensitivity Reactions: Cytolytic Reactions

Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...

Cytotoxic Edema: Pathophysiology

Cytotoxic Edema: Pathophysiology

Cytotoxic edema is a form of cerebral edema characterized by intracellular swelling of neurons, astrocytes, and other glial cells. It develops when the mechanisms responsible for maintaining ionic gradients across the cell membrane become impaired. Under normal physiological conditions, the sodium–potassium ATPase actively transports sodium ions out of the cell and potassium ions into the cell, preserving osmotic balance and enabling electrical signaling. This pump requires a continuous...

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

Autoimmune Disorders

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Identifying the best predictive diagnostic criteria for psoriasis in children (< 18 years): a UK multicentre case-control diagnostic accuracy study (DIPSOC study).

The British journal of dermatology·2021

Same author

Frontal fibrosing alopecia: a descriptive cross-sectional study of 711 cases in female patients from the UK.

The British journal of dermatology·2020

Same author

Developing classification criteria for skin-predominant dermatomyositis: the Delphi process.

The British journal of dermatology·2019

Same author

An unusual eruption following herpes zoster infection.

Clinical and experimental dermatology·2018

Same author

Sustained response of graft-versus-host disease-associated angiomatosis treated with propranolol.

Clinical and experimental dermatology·2018

Same author

Antibiotic resistance rates in cutaneous propionibacteria from UK patients with acne are not falling.

Clinical and experimental dermatology·2017

Search research articles

Related Experiment Video

Updated: Apr 27, 2026

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

Multiple halo naevi associated with tocilizumab.

K Kuet¹, M Goodfield

¹Department of Dermatology, Chapel Allerton Hospital, Leeds, West Yorkshire, UK.

Clinical and Experimental Dermatology

|July 3, 2014

Summary

Tocilizumab treatment for juvenile idiopathic arthritis (JIA) was associated with the development of halo nevi. This suggests interleukin-6 (IL-6) signaling may influence melanocyte function and immune responses.

Area of Science:

Immunology
Dermatology
Oncology

Background:

Tocilizumab targets the interleukin-6 (IL-6) receptor, approved for rheumatoid arthritis and juvenile idiopathic arthritis (JIA).
Interleukin-6 (IL-6) is a cytokine implicated in cancer immunity and melanocyte function, with elevated levels observed in vitiligo.

Observation:

A case of multiple halo nevi developed in a patient with a history of JIA undergoing tocilizumab treatment.
Halo nevi are benign lesions characterized by a depigmented halo surrounding a central nevus.

Findings:

Tocilizumab's mechanism may involve immune system modulation, potentially leading to halo nevus formation.
Altered epidermal cytokine profiles due to increased serum IL-6 levels from tocilizumab could directly inhibit melanocytes.

More Related Videos

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

Related Experiment Videos

Last Updated: Apr 27, 2026

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

Implications:

This case highlights a potential dermatological side effect of tocilizumab therapy.
Further research is warranted to elucidate the precise role of IL-6 in melanocyte biology and immune-related dermatoses.